They're already there—you just need to learn how to get them to behave the way you want.
Since antiquity, the capacity of certain creatures to regrow lost limbs has stood as one of nature's most humbling mysteries — a gift withheld, it seemed, from mammals by some deep biological decree. Now, researchers at Texas A&M University have demonstrated that mice harbor a dormant regenerative potential, successfully regrowing toe structures using two signaling proteins that redirect the body's own wound-healing cells. The discovery does not yet promise human limb regeneration, but it quietly dismantles the assumption that such a thing is impossible — suggesting the machinery may already exist within us, waiting to be addressed.
- The long-held boundary between scarring and regeneration has been crossed in a mammal for the first time, using only proteins and the body's existing cells.
- The critical tension lies in the body's default response to injury: fibroblast cells rush to seal wounds with scar tissue, actively suppressing the very regenerative pathway researchers are now trying to unlock.
- By sequencing two proteins — FGF2 to reprogram fibroblasts away from scarring, then BMP2 to instruct them to build bone, tendons, and ligaments — the team successfully triggered blastema formation, the same cellular structure salamanders use to regrow limbs.
- The regrown toes were imperfect, sometimes misshapen or undersized, but structurally complete — a proof of concept that shifts the scientific question from 'whether' to 'how well.'
- With BMP2 already cleared for surgical use and FGF2 advancing through approval, the near-term horizon points toward improved wound repair and reduced scarring, even before full regeneration in humans becomes viable.
Salamanders regrow entire limbs. Humans grow scars. That divide has long felt absolute — but a team at Texas A&M University has now shown it may be more negotiable than biology once suggested. Using just two proteins and the body's own cells, they coaxed a mouse to regrow a missing toe, complete with bone, tendons, and ligaments.
The insight driving the work is deceptively simple. When injury occurs, fibroblast cells converge on the wound and default to patching it with scar tissue. But in that active, malleable state, those same cells can be redirected. Regenerative biologist Ken Muneoka describes the process in two steps: first, pull the cells away from the scarring pathway; then, tell them what to build instead.
FGF2 handles the first step, reprogramming fibroblasts to form a blastema — the temporary cellular bud that regenerating animals use as a scaffold for regrowth. BMP2 then delivers the construction instructions, prompting the blastema to lay down skeletal and connective tissue. In tests across dozens of mice, the combination worked. The regrown digits were sometimes imperfect in shape, but structurally real.
What distinguishes this approach is that it requires no external stem cells. The necessary cells are already present in the wound tissue — the challenge is learning how to activate them. Earlier experiments from the same lab, lacking FGF2, never achieved blastema formation and fell short of full regrowth. That first signaling step, it turns out, is what opens the door.
The road to human application remains long, and the regrown structures will need to more closely match what was lost. But both proteins are already in or near clinical use, meaning near-term benefits — better wound healing, reduced scarring — may arrive well before full regeneration becomes viable. A question that has shadowed biology since Aristotle may, at last, be yielding an answer.
Salamanders can grow back entire limbs. Axolotls can do the same. Humans, by contrast, are stuck with scars. But a team at Texas A&M University has just demonstrated that this gap might not be as permanent as we thought. They coaxed a mouse to regrow a missing toe—not perfectly, but unmistakably—using nothing more than two proteins and the body's own cells.
The breakthrough hinges on a simple biological insight: when we get injured, our bodies have two possible responses. The default is scarring. Fibroblast cells rush to the wound and patch it with scar tissue, which stops the bleeding but abandons any hope of regeneration. But those same fibroblasts, while actively working, exist in a peculiar state—receptive, malleable, ready to be redirected. Ken Muneoka, the regenerative biologist leading the work, describes it as a two-step process: first, shift the cells away from their scarring pathway; then, tell them what to build instead.
The first step uses a protein called fibroblast growth factor 2, or FGF2. It essentially reprograms the fibroblasts, preparing them to transform into something entirely different: a blastema. This is the temporary cellular bud that salamanders and other regenerating animals use to prepare tissue not just for repair but for actual regrowth. Once that foundation is laid, a second protein enters the picture. Bone morphogenetic protein 2, or BMP2, delivers the instructions for construction. It tells the blastema to start building—to lay down bone, tendons, ligaments, and joint structures.
In tests across dozens of mice, the double-protein treatment worked. The regrown toes were sometimes misshapen or undersized, but they contained all the essential skeletal and connective tissue elements of a real digit. The bones were there. The tendons were there. The ligaments were there. What had been lost was, in a meaningful sense, restored.
What makes this approach unusual in regenerative medicine is that it doesn't rely on introducing new stem cells from outside the body. Those cells are already present in the tissue around the wound. The innovation is learning how to wake them up and point them in the right direction. "You don't have to actually get stem cells and put them back in," Muneoka explains. "They're already there—you just need to learn how to get them to behave the way you want."
This work builds on earlier experiments from the same lab, but with a crucial difference. Previous attempts lacked FGF2, never formed a blastema, and only partially regrew the missing limb. The addition of that first signaling step—the shift away from scarring—appears to be what unlocks fuller regeneration. Co-author Larry Suva, a veterinary physiologist, frames the significance plainly: "Once you show that regeneration can be activated, it opens the door to asking entirely new questions."
The path from mice to humans is long. Researchers need to understand the regrowth mechanisms more deeply and produce limbs that more closely match what was lost. But there's reason for near-term optimism. BMP2 is already approved for use in reconstructive surgery. FGF2 is moving through the approval pipeline. Even before full limb regeneration becomes viable in humans, these proteins could improve wound repair and reduce scarring—a meaningful benefit on its own. The question that has haunted biology since Aristotle—why some animals can regenerate and others cannot—may finally have an answer. And that answer, it turns out, might be hiding inside us all along.
Notable Quotes
You first shift the cells away from scarring, and then you provide the signals that tell them what to build.— Ken Muneoka, regenerative biologist at Texas A&M University
Once you show that regeneration can be activated, it opens the door to asking entirely new questions.— Larry Suva, co-author and veterinary physiologist
The Hearth Conversation Another angle on the story
So the mice actually grew back a functional toe? What does that look like?
Not perfect—sometimes misshapen, sometimes too small. But the structure was all there. Bone, tendons, ligaments, joints. The biological blueprint was intact, even if the execution was rough.
And this only worked because they used two proteins, not one?
Exactly. The first protein, FGF2, essentially tells the body to stop scarring and start preparing for regeneration. The second, BMP2, gives the actual building instructions. One without the other doesn't get you the same result.
But these proteins already exist in the body, right? So why don't we just regenerate naturally?
That's the mystery. We have the cellular machinery. We have the proteins. But somewhere in our evolutionary history, mammals—especially humans—lost the ability to activate that machinery after injury. The scarring response took over instead.
If this works in humans, what's the timeline?
That's the honest part: we don't know yet. There's a lot of testing ahead. But BMP2 is already approved for surgery, and FGF2 is close. So even if full limb regeneration takes years, we might see better wound healing and less scarring much sooner.
Does this change how we think about disability?
It opens a door. Whether it actually walks through that door depends on whether the science scales. But yes—if regeneration is possible, it fundamentally shifts what we think is possible.